These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29735936)

  • 41. Botulinum toxin for the treatment of refractory erythema and flushing of rosacea.
    Park KY; Hyun MY; Jeong SY; Kim BJ; Kim MN; Hong CK
    Dermatology; 2015; 230(4):299-301. PubMed ID: 25765295
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intradetrusor injection of botulinum toxin A and sacral neuromodulation for neurogenic detrusor overactivity.
    Joussain C; Phé V; Even A; Chartier-Kastler E; Denys P
    Eur J Phys Rehabil Med; 2017 Dec; 53(6):991-997. PubMed ID: 29072045
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glutamate receptors and Parkinson's disease: opportunities for intervention.
    Marino MJ; Valenti O; Conn PJ
    Drugs Aging; 2003; 20(5):377-97. PubMed ID: 12696997
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
    Chagniel L; Robitaille C; Lebel M; Cyr M
    Neurobiol Dis; 2012 Jan; 45(1):645-55. PubMed ID: 22037042
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An update on the use of botulinum toxin therapy in Parkinson's disease.
    Mills R; Bahroo L; Pagan F
    Curr Neurol Neurosci Rep; 2015 Jan; 15(1):511. PubMed ID: 25407133
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intraprostatic Botulinum Neurotoxin Type A Injection for Benign Prostatic Hyperplasia-A Spotlight in Reality.
    Hsu YC; Wang HJ; Chuang YC
    Toxins (Basel); 2016 Apr; 8(5):. PubMed ID: 27128942
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of severe drooling with botulinum toxin in amyotrophic lateral sclerosis and Parkinson's disease: efficacy and possible mechanisms.
    Møller E; Karlsborg M; Bardow A; Lykkeaa J; Nissen FH; Bakke M
    Acta Odontol Scand; 2011 May; 69(3):151-7. PubMed ID: 21198339
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.
    Dressler D; Bigalke H; Benecke R
    J Neurol; 2003 Aug; 250(8):967-9. PubMed ID: 12928917
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Functional impact of different muscle localization techniques for Botulinum neurotoxin A injections in clinical routine management of post-stroke spasticity.
    Zeuner KE; Knutzen A; Kühl C; Möller B; Hellriegel H; Margraf NG; Deuschl G; Stolze H
    Brain Inj; 2017; 31(1):75-82. PubMed ID: 27880052
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting striatal metabotropic glutamate receptor type 5 in Parkinson's disease: bridging molecular studies and clinical trials.
    Vallano A; Fernandez-Duenas V; Garcia-Negredo G; Quijada MA; Simon CP; Cuffí ML; Carbonell L; Sanchez S; Arnau JM; Ciruela F
    CNS Neurol Disord Drug Targets; 2013 Dec; 12(8):1128-42. PubMed ID: 24040811
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Botulinum toxin injection for facial wrinkles.
    Small R
    Am Fam Physician; 2014 Aug; 90(3):168-75. PubMed ID: 25077722
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease.
    Obeso JA; Rodríguez-Oroz MC; Benitez-Temino B; Blesa FJ; Guridi J; Marin C; Rodriguez M
    Mov Disord; 2008; 23 Suppl 3():S548-59. PubMed ID: 18781672
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Botulinum toxin type A and type B for sialorrhoea in Parkinson's disease: a case for switching therapy?
    Santamato A; Panza F; Solfrizzi V; Frisardi V; Ranieri M; Fiore P
    J Rehabil Med; 2008 Nov; 40(10):882-3. PubMed ID: 19242630
    [No Abstract]   [Full Text] [Related]  

  • 55. Botulinum toxin for chronic migraine: Clinical trials and technical aspects.
    Tassorelli C; Sances G; Avenali M; De Icco R; Martinelli D; Bitetto V; Nappi G; Sandrini G
    Toxicon; 2018 Jun; 147():111-115. PubMed ID: 28877509
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Short- and long-term effects induced by repeated 6-OHDA intraventricular administration: A new progressive and bilateral rodent model of Parkinson's disease.
    Quiroga-Varela A; Aguilar E; Iglesias E; Obeso JA; Marin C
    Neuroscience; 2017 Oct; 361():144-156. PubMed ID: 28823819
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders.
    Luvisetto S; Gazerani P; Cianchetti C; Pavone F
    Toxins (Basel); 2015 Sep; 7(9):3818-44. PubMed ID: 26404377
    [TBL] [Abstract][Full Text] [Related]  

  • 58. More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system.
    Mazzocchio R; Caleo M
    Neuroscientist; 2015 Feb; 21(1):44-61. PubMed ID: 24576870
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway.
    Booij J; Berendse HW
    J Neurol Sci; 2011 Nov; 310(1-2):40-3. PubMed ID: 21840542
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Improvement of idiopathic Raynaud's phenomenon following local infusion of botulinum toxin].
    Roguedas AM; Misery L
    Ann Dermatol Venereol; 2014; 141(6-7):462-3. PubMed ID: 24951147
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.